By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bioinformatics firm Symyx Technologies today said that its board of directors has determined that a bid from Certara to acquire the firm for $5.75 per share in cash does not represent a superior offer to an earlier bid from Accelrys.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.